Abstract

The human toxoplasmosis is a disease caused by the parasite Toxoplasma gondii that can affect the growing baby in pregnancy and it is the most common CNS infection in patients with AIDS. Its treatment is made by the synergistic association of the drugs pyrimethamine (PM) and sulfadiazine (SDZ). Objective: the aim of this study was to evaluate if the use of the combination of PM and SDZ changes the sodium pertechnetate (Na99mTcO4-) biodistribution in non-infected animals by the T. gondii. It was used 24 male Swiss mice equally divided into 4 groups: 1 control group and 3 treated groups. Methods: the control group received 0.5 mL of distilled water; the treated group 1 received 0.5 mL of a PM solution; the treated group 2 received 0.5 mL of a SDZ solution and the treated group 3 received 0.5 mL of the PM+SDZ, all by the gavage method for 10 days. On the 10th day and 1 h after the last dose, all groups received 0.1mL of Na99mTcO4- (0.66MBq) via the femoral vein. After 40 min, the animals were euthanized, and blood and brain samples were isolated. The percentage of total activity injected per gram of organ (%ATI/g) was calculated on the gamma counter. Statistical analysis were performed using the T-test, considering a level of significance of p

Key words: Anti-Toxoplasma drugs. Synergistic drugs. Sodium pertechnetate. Toxoplasma gondii. Sulfadiazine. Pyrimethamine.